A Diagnostics & Imaging Week

Caliper Life Sciences (Hopkinton, Massachusetts) reported that Novartis (Basel, Switzerland) has signed a multi-year license to Caliper's patented non-invasive optical imaging methods.

Non-invasive optical imaging, an increasingly critical technology for drug discovery and development, allows scientists to visualize, track and quantify biological processes at the molecular level in living animals with high throughput and relatively low cost. Caliper provides commercial and academic customers with a selection of in vivo offerings including imaging systems, reagents, applications, patented methods and services that improve drug discovery and development efforts.

Caliper's Xenogen family of IVIS instrument systems, reagents, and proprietary methods are designed to deliver non-invasive in vivo imaging along with high sensitivity, ease of use and exceptional data quality.

Caliper Life Sciences is a provider of technologies enabling researchers in the life sciences to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Novartis offers a wide range of healthcare products through its pharmecuticals, vaccines and diagnostics and consumer health divisions.

No Comments